TABLE 2.
Transplant details.
| Parameter | HL (n = 24) |
|---|---|
| Median age of recipient at transplant; years, range | 27 (18–44) |
| Disease status at allo-SCT; n, % | |
| CR | 4 (16) |
| PR | 10 (42) |
| SD | 10 (42) |
| Median age of donor at transplant; years, range | 30 (19–51) |
| Type of donor; n, % | |
| Matched sibling donor | 9 (38) |
| Unrelated donor | 15 (62) |
| Stem cell source; n, % | |
| Bone marrow | 7 (29) |
| Peripheral blood | 16 (67) |
| Bone marrow and peripheral blood | 1 (4) |
| Donor-recipient sex matching; n, % | |
| Donor male-recipient female | 4 (16) |
| Donor female-recipient male | 6 (25) |
| Sex matching | 14 (58) |
| ABO-blood group matching; n, % | |
| Matched | 10 (42) |
| Minor mismatch | 9 (38) |
| Major mismatch | 3 (13) |
| Minor and major mismatch | 2 (7) |
| Type of conditioning; no, % | |
| BuFlu | 16 (67) |
| FluMelAlem | 5 (21) |
| MelTBI | 2 (8) |
| BEAM | 1 (4) |
| GVHD prophylaxis; no, % | |
| CsA + Mtx | 19 (79) |
| MMF + Mtx | 3 (13) |
| TAC + MMF | 1 (4) |
| TAC + MMF+ post Cy | 1 (4) |
| Median number of transplanted CD34-positive cells (x106/kg); range | 5.0 (1.37–9.32) |
| Median number of transplanted CD3-positive cells (x107/kg); range | 14.4 (1.46–52.4) |
| Median ANC>0.5 (x109/L); days, range | 18 (13–24) |
| Median PLT >20 (x109/L); days, range | 13 (8–23) |
| Disease status of survivors; n, % | 7 (100) |
| CR | 6 (86) |
| PR | 1 (14) |
allo-SCT, allogeneic stem cell transplantation; ANC, absolute neutrophil count; BEAM, carmustine, etoposide, cytarabine, melphalan; BuFlu, busulphan, fludarabine; CR, complete remission; CsA, cyclosporine; Cy, cyclophosphamide; FluMelAlem, fludarabine, melphalan, alemtuzumab; GVHD, graft versus host disease; MelTBI, melphalan, total body irradiation; MMF, mycofenolan mofetil; Mtx, methotrexate; PLT, platelets; PR, partial response; SD, stable disease; TAC, tacrolimus.